The introduction of immune checkpoint inhibitors such as Keytruda (Merck & Co.), Opdivo + Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; U.S. only), as well as BRAF / MEK…
Epi Data Slicer
Disease stage, primary tumor resectability, and BRAF mutation status are key parameters influencing the treatment paradigm of malignant melanoma patients. BRAF/MEK inhibitor combination regimens,…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…
The treatment of BRAF mutation-positive unresectable or metastatic malignant melanoma has been transformed by the development of immune checkpoint inhibitors (e.g., Keytruda, Opdivo, Tecentriq) and…
Clarivate Epidemiology’s coverage of malignant melanoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of malignant melanoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…
DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key endometrial cancer patient populations covering 171 countries and more than…
Clarivate Epidemiology’s coverage of malignant melanoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of malignant melanoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of malignant melanoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…